Meritage Portfolio Management Sells 86,662 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Meritage Portfolio Management lessened its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 58.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,891 shares of the company's stock after selling 86,662 shares during the quarter. Meritage Portfolio Management's holdings in Roche were worth $2,206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Yousif Capital Management LLC boosted its position in Roche by 6.9% during the fourth quarter. Yousif Capital Management LLC now owns 99,124 shares of the company's stock worth $3,599,000 after purchasing an additional 6,440 shares during the period. GAMMA Investing LLC bought a new stake in shares of Roche during the 4th quarter worth about $146,000. Cable Hill Partners LLC acquired a new position in Roche in the 4th quarter valued at about $464,000. Wetzel Investment Advisors Inc. bought a new position in Roche in the 4th quarter valued at about $53,000. Finally, Hikari Power Ltd lifted its position in Roche by 0.8% during the fourth quarter. Hikari Power Ltd now owns 237,820 shares of the company's stock worth $8,616,000 after acquiring an additional 2,000 shares during the last quarter.

Roche Price Performance

Shares of OTCMKTS RHHBY traded down $0.52 during mid-day trading on Thursday, hitting $30.02. 3,930,578 shares of the stock traded hands, compared to its average volume of 2,425,558. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.75. Roche Holding AG has a twelve month low of $29.80 and a twelve month high of $40.48. The firm has a 50 day simple moving average of $31.95 and a two-hundred day simple moving average of $33.65.

Analyst Upgrades and Downgrades

RHHBY has been the topic of a number of research reports. Morgan Stanley lowered Roche from an "equal weight" rating to an "underweight" rating in a report on Tuesday, January 16th. Argus reiterated a "hold" rating on shares of Roche in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $40.00.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.